IXICO PLC
LSE:IXI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Golden Tag Resources Ltd
XTSX:GOG
|
CA |
|
H
|
Hiscox Ltd
OTC:HCXLY
|
BM |
|
Tripod Technology Corp
TWSE:3044
|
TW |
|
180 Life Sciences Corp
NASDAQ:ATNF
|
US |
|
I
|
Immunovia AB (publ)
OTC:IMMVF
|
SE |
|
Fujian Expressway Development Co Ltd
SSE:600033
|
CN |
|
B
|
Buligo Capital Ltd
TASE:BLGO
|
IL |
|
Wanderport Corp
OTC:WDRP
|
US |
|
New Asia Holdings Inc
OTC:NAHD
|
SG |
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
|
IXICO PLC
LSE:IXI
|
6.8m GBP |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
992.2B USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
186.6B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
134B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
316.8B CNY |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
34.7B CHF |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.5B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
31.4B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.4B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27B USD |
Loading...
|
Market Distribution
| Min | -188 120% |
| 30th Percentile | 0% |
| Median | 0% |
| 70th Percentile | 0.1% |
| Max | 10 443.9% |
Other Profitability Ratios
IXICO PLC
Glance View
IXICO Plc engages in the provision of technology-enabled specialty services to the global biopharmaceutical industry. The Company’s data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable trial design, site qualification, patient selection and clinical outcomes. The company provides technology-enabled services across all phases of clinical evaluation. The Company’s services include the collection, analysis, management and reporting of data generated during a clinical study and the outputs from the data analysis. The Company’s integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make better-informed decisions. Its geographical area includes Switzerland, United Kingdom, United States of America, Netherlands, Ireland and Europe.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for IXICO PLC is -25.3%, which is below its 3-year median of -21.9%.
Over the last 3 years, IXICO PLC’s Net Margin has decreased from 11.9% to -25.3%. During this period, it reached a low of -34.7% on Sep 30, 2024 and a high of 11.9% on Sep 30, 2022.
